Clinical Trials >> COPD (Chronic Obstructive Pulmonary Disease)

COPD (Chronic Obstructive Pulmonary Disease)

People with COPD are commonly treated with drugs delivered by a metered-dose inhaler (MDI).  An MDI is a device that delivers a set amount of medication to the lungs in a short burst of gas upon inhalation. This study wants to find out if the propellant (liquid compressed gas) called hydrofluoroolefin (HFO), which helps deliver the drug from the inhaler, is as safe and easy to tolerate by your body, as the currently used liquid gas called hydrofluoroalkane (HFA).   

HFO is being tested because it has a near-zero Global Warming Potential (GWP) and is more friendly to the environment than the currently used HFA due to being less harmful to the atmosphere.

 This study will last from 12-52 weeks. 

A few qualifications to participate are: 

  • Participants must be 40 to 80 years of age inclusive 
  • Participants who have a documented history of diagnosed COPD 
  • Participants who have been regularly using dual ICS/LABA, LAMA/LABA, or ICS/LAMA/LABA (open or fixed-dose combinations) inhaled maintenance therapies for the management of their COPD for at least 6 weeks prior to Screening


Currently Enrolling Studies

We are currently seeking participants for different clinical research studies. Click below to learn about our current trials and summit your information. We will reach out to you very quickly to answer any questions you may have and see if you qualify.